Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study

The adjusted incidence rate of new-onset atrial fibrillation was 8.6 per 1,000 person-years for new users of SGLT2 inhibitors.

• New users of SGLT2 inhibitors had a lower adjusted hazard ratio of 0.89 for new-onset atrial fibrillation compared to those using GLP-1 receptor agonists.
• The adjusted incidence rate for new users of GLP-1 receptor agonists was 10.0 per 1,000 person-years.
• A rate difference of 1.4 fewer events per 1,000 person-years was observed for new users of SGLT2 inhibitors.
• Using an as-treated exposure definition, the adjusted hazard ratio for new-onset atrial fibrillation was 0.87.
• No significant differences in the adjusted hazard ratios were found between patients with and without a history of heart failure or major cardiovascular disease.

AI simplified